Vardenafil 20 mg is a labeled strength of conventional film-coated prescription tablets for erectile dysfunction. Its presence in U.S. prescribing information identifies a product presentation; it is not a recommendation for someone to increase their prescribed dose or a sign that the tablet is inherently better than other treatment options.
Clinical suitability depends on a licensed prescriber’s assessment of response, tolerability, other medicines and cardiovascular considerations. Vardenafil has important contraindications involving nitrates and riociguat, and label-specific cautions for QT prolongation and relevant antiarrhythmics. A stronger numerical label does not make those safety considerations optional. The conventional 20 mg ceiling also does not apply unchanged in every clinical situation, notably moderate hepatic impairment and treatment with strong CYP3A4 inhibitors.
This article focuses on the 20 mg film-coated product’s regulatory identity and safe interpretation. The strengths catalog compares labeled options; the dosage guide explains how clinicians approach selection without turning a product page into self-prescribing instructions.
Vardenafil hydrochloride 20 mg is a conventional oral tablet strength appearing in U.S. prescription product labeling. The precise finished medicine is defined not only by the ingredient and strength but also by its approved application, dosage form, labeling and manufacturer or labeler.
Generic tablets from different approved applicants may vary in nonactive components and visual appearance. The pharmacy label and product identity—not a marketplace image—should be used to determine what was actually dispensed.
Twenty milligrams is the maximum recommended conventional vardenafil film-coated dose in the usual U.S. as-needed ED labeling, not a universal choice or a routine starting dose. It is not a daily maintenance medicine, and an unsatisfactory response does not justify another tablet or an independent increase. Sexual stimulation remains necessary.
Important clinical ceilings can be much lower than 20 mg. The exact product label, current medicines and liver or kidney status must be checked before assuming the ordinary maximum applies. The administration guide addresses practical use, and the dosage guide owns the broader restrictions.
A milligram number has meaning only within the same active ingredient and labeled formulation. It cannot establish a head-to-head efficacy ranking against sildenafil or tadalafil, nor can it demonstrate that every patient will benefit more from 20 mg than from another prescribed vardenafil strength.
Adverse effects and interactions may constrain treatment as well as efficacy. For product-level information about other conventional strengths, see 10 mg film-coated vardenafil and 5 mg vardenafil instead of using an unsupervised dose escalation.
A sound product check ties the strength to the precise dosage form and legal dispensing record. The table covers stable identification fields, not clinical dose recommendations.
If the supplied product differs from the prescription, a pharmacist should resolve it with the prescriber before the patient uses it.
| Product check | Expected information | Potential mistake |
|---|---|---|
| Active ingredient | Vardenafil hydrochloride | Confusing it with another PDE5 drug |
| Strength | 20 mg film-coated tablet | Assuming stronger always means preferable |
| Dosage form | Conventional tablet | Confusing it with 10 mg ODT |
| Applicant and imprint | Identifiable approved generic product | Trusting an unrelated product photograph |
| Prescribed instructions | Clinician-directed as-needed regimen | Self-escalating or combining products |
| Pharmacy stock | Specific current supply confirmation | Treating old brand results as inventory |
Vardenafil has a specific warning related to prolongation of the QT interval. Patients with congenital long-QT syndrome or those using certain Class IA or Class III antiarrhythmics are generally advised to avoid vardenafil according to labeling. The decision cannot be made from a tablet strength alone.
The prescriber should also consider other medicine exposures that change vardenafil concentrations or affect blood pressure. The interactions guide separates these issues by mechanism and medicine class.
The U.S. film-coated vardenafil label sets a maximum of 10 mg in moderate hepatic impairment (Child-Pugh B) and advises against use in severe hepatic impairment (Child-Pugh C) or renal dialysis. Therefore, a prescribed 20 mg product can be inappropriate in circumstances in which a lower ceiling—or avoidance—is explicitly required. These are label-based clinical boundaries, not instructions to split a tablet.
Important CYP3A4 inhibitors can impose stricter limits still. For example, certain current labels restrict coadministration with ritonavir or cobicistat to no more than 2.5 mg over 72 hours, with distinct limits for other named inhibitors. Patients should have all medicines reviewed rather than assume the highest commercial tablet strength remains an option. The detailed dosage guide explains the exceptions.
Patients taking nitrates, nitric-oxide donors or riociguat must not use vardenafil in combination with those drugs. Lowering the amount or spacing doses without clinical direction is not a safe workaround. Any new chest pain or serious symptoms requires prompt professional evaluation.
Clinicians involved in emergency care need to know about recent PDE5-inhibitor exposure. Patients should carry an up-to-date medicine list and seek advice before adding any interacting prescription or supplement.
The historic Staxyn brand and certain generic vardenafil ODT products use a 10 mg dissolving formulation with different exposure. A 20 mg film-coated tablet is not a substitute simply because someone can compare or divide the milligram numbers.
Formulation, strength and administration method must match the lawful prescription. The ODT guide provides the separate product context, while the Staxyn page covers brand history.
Vardenafil can produce headache, flushing, nasal symptoms, dyspepsia and other reported adverse effects; individual tolerability varies. A higher labeled strength should not be interpreted as harmless simply because it is FDA-approved.
An erection lasting more than four hours requires emergency care, and sudden vision or hearing loss warrants stopping the medication and prompt medical attention. The side-effects guide explains routine versus urgent symptoms.
A database listing can show an approved vardenafil 20 mg tablet formulation without establishing that a specific pharmacy has it in stock or that insurance will pay for it. A retail quote should match the exact film-coated generic, prescribed quantity and service conditions.
Use the availability guide to check supply and the cost guide to understand durable pricing factors, without relying on promotional price snippets.
If prescribed 20 mg vardenafil, confirm the active product, current medical history, concurrent medicines and the pharmacy’s exact dispensing plan. The pharmacist should be available to answer questions about appearance, directions, interactions and substitutions.
For a lawful U.S. fulfillment route, see the vardenafil purchasing guide. Never order foreign or no-prescription versions of this strength on the assumption that identical milligrams ensure FDA approval or safety.
Yes. It is included in the U.S. conventional film-coated vardenafil tablet-strength family.
No. Treatment response and tolerability vary, and a higher number does not automatically mean a better clinical result.
No. Strength selection and changes belong to the prescribing clinician after reviewing response and risks.
The conventional 20 mg presentation is film-coated; separate vardenafil ODT products have different 10 mg labeling.
Yes. Vardenafil must not be used with nitrates or riociguat, regardless of the labeled strength.
Vardenafil has QT-prolongation warnings, particularly relevant with certain heart-rhythm conditions and antiarrhythmic medicines.
The original U.S. Levitra branded presentations were discontinued. Check independently approved generic film-coated products.
No. Ask the licensed pharmacy to verify current stock of the exact prescribed product, form and quantity.
Not necessarily. In moderate hepatic impairment, the film-coated label caps dosing at 10 mg; with ritonavir or cobicistat it can specify no more than 2.5 mg per 72 hours. Severe liver impairment and renal dialysis carry additional restrictions. A clinician must evaluate the exact product and circumstances.